← back to search

Meiying Shen

Harbin Medical University · CN
🔎 Find collaborators in Infectious Diseases · Oncology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Infectious Diseases · Oncology
Research interest
Research focused on Avidity and Cytotoxic T cell, with related work in Monoclonal antibody, Neutralization, Epitope. Notable publications include 'Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants', 'Long Noncoding RNAs Control the Modulation of Immune Checkpoint Molecules in Cancer', and 'IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities'.
h-index
citations
422
works
20
NIH funding
primary concept
email

Recent publications

Age heterogeneity in the association between malnutrition and early childhood development among children aged 0–5 years in a Chinese plateau area
Public Health 2025cited by 1position: firstdoi
Prophylactic efficacy of an intranasal spray with 2 synergetic antibodies neutralizing Omicron
JCI Insight 2024cited by 4position: middledoi
Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium
Cell Reports 2023cited by 41position: middledoi
Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants
Genes & Diseases 2021cited by 54position: middledoi
IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities
Frontiers in Molecular Biosciences 2021cited by 53position: middledoi
Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
Nature Communications 2021cited by 50position: middledoi
A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2
Frontiers in Immunology 2021cited by 33position: middledoi
p38 inhibition enhances TCR-T cell function and antagonizes the immunosuppressive activity of TGF-β
International Immunopharmacology 2021cited by 16position: middledoi
TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
Frontiers in Molecular Biosciences 2021cited by 12position: middledoi
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 4position: middledoi
TRAIL-R1-targeted chimeric antigen receptor T cells exhibit dual antitumor effects
2021cited by 1position: middledoi
Long Noncoding RNAs Control the Modulation of Immune Checkpoint Molecules in Cancer
Cancer Immunology Research 2020cited by 54position: middledoi
Identification of long-term survival-associated gene in breast cancer
Aging 2020cited by 30position: middledoi
A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 12position: middledoi
Identification of Cross-Reactive CD8 <sup>+</sup> T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 8position: middledoi
A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 7position: middledoi
Immune characteristics analysis reveals two key inflammatory factors correlated to the expressions of SARS-CoV-2 S1-specific antibodies
Genes & Diseases 2020cited by 6position: middledoi
A rapid and efficient screening system for neutralizing antibodies and its application for SARS-CoV-2
Research Square 2020cited by 2position: middledoi
Long Noncoding RNA Linc00152 Functions as a Tumor Propellant in Pan-Cancer
Cellular Physiology and Biochemistry 2017cited by 26position: middledoi
Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1
Journal of Cancer 2017cited by 2position: middledoi
Fully human monoclonal antibodies to TRAIL-R1 enhance TRAIL-induced apoptosis via activation of caspase-8 pathway
Biochemical and Biophysical Research Communications 2016cited by 10position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Da Pang · First People's Hospital of Foshan10 papers (2016–2021)Aishun Jin · Harbin Medical University9 papers (2016–2021)Xiaojian Han · Nanchang University9 papers (2016–2021)Wang Wang · Nanchang University6 papers (2020–2021)Jingjing Huang · Nanjing University of Chinese Medicine5 papers (2016–2021)Li Du · Children's Hospital of Zhejiang University5 papers (2020–2021)Chao Hu · Suizhou Central Hospital4 papers (2020–2021)Shenglong Li · Nantong University4 papers (2020–2021) · 4 papers (2020–2021)Shouping Xu · The First Affiliated Hospital, Sun Yat-sen University3 papers (2017–2020)Tingting Li · Xiamen University3 papers (2020–2021)Jianwei Wang · Chengdu University of Traditional Chinese Medicine3 papers (2020–2021)Yingming Wang · Anhui Medical University3 papers (2020–2021)Kun Tao · Virginia Commonwealth University3 papers (2020–2021) · 3 papers (2020–2021)Wei Zheng · Army Medical University2 papers (2017–2020)Li Luo · South China Agricultural University2 papers (2021–2021)Yaying Li · Shandong University of Traditional Chinese Medicine2 papers (2016–2017)Fengxia Gao · The Ohio State University2 papers (2020–2021)Xin Sun · Nantong University2 papers (2016–2017)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Infectious Diseases · Oncology →